FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

As supply chain disruption persists in pharma, global logistics providers with the expertise to overcome any challenge are essential.

Acumen has entered a partnership, option and licence agreement with JCR for developing an oligomer-targeted EBD for Alzheimer’s disease.

The acquisition includes dne pharma’s entire business, encompassing its product portfolio. Credit: MOLEQL/Shutterstock. Oslo, Norway-headquartered Navamedic has completed its previously announced ...

Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.

Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme.

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) for HoFH.

WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

Amid general supply chain disruption, scaling pharma businesses need expert logistics partners on hand to achieve growth.

Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.